UPDATE: Deutsche Bank Downgrades Amedisys Following Q3 Miss
November 13, 2013 at 10:15 AM EST
In a report published Wednesday, Deutsche Bank analyst Darren Lehrich downgraded the rating on Amedisys (NASDAQ: AMED ) from Hold to Sell, and lowered the price target from $11.00 to $8.00. In the report, Deutsche Bank noted, “AMED's Q3 miss provides further evidence that the co's operations are unstable, and
